耐受原性因子VIII预防血友病A抑制物形成
本研究评估耐受原性因子VIII(FVIII)纳米颗粒在血友病A小鼠中预防抑制物的效果。FVIII与含溶血磷脂酰丝氨酸(Lyso-PS)的纳米颗粒结合后静脉给药,可显著减少抑制物形成并改善FVIII血浆存活;口服Lyso-PS纳米颗粒也能减少抑制物形成。
要点
- Lyso-PS纳米颗粒偶联FVIII静脉给药可减少抑制物并改善FVIII血浆存活。
- 口服Lyso-PS纳米颗粒同样可减少抑制物形成。
- 该策略有望作为预防血友病A抑制物的免疫治疗。
核心结论
- FVIII与Lyso-PS纳米颗粒结合静脉给药可显著减少抑制物形成并改善FVIII血浆存活。
- 口服Lyso-PS纳米颗粒也可减少抑制物形成。
研究设计与样本
- 研究在血友病A小鼠中进行,FVIII与含Lyso-PS的纳米颗粒经静脉途径给药。
- 动物随后每周接受游离FVIII再攻击注射,研究结束时采集血浆评估抑制物形成。
- 进行药代动力学研究:单次静脉给予FVIII,比较有无Lyso-PS纳米颗粒时的血浆存活。
- 还检查了口服给予Lyso-PS纳米颗粒后的耐受原性效果。
主要发现
- 静脉给药时,FVIII与Lyso-PS纳米颗粒结合显著减少抑制物形成。
- 静脉给药时,FVIII与Lyso-PS纳米颗粒结合改善FVIII血浆存活。
- 口服Lyso-PS纳米颗粒也可减少抑制物形成。
临床怎么用
- Lyso-PS纳米颗粒偶联FVIII可能作为预防血友病A抑制物形成的免疫治疗策略。
- 口服Lyso-PS纳米颗粒提供了一种方便给药的抑制物预防途径。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The development of antidrug antibodies, also termed inhibitors, against administered factor VIII (FVIII) is one of the major complications in the clinical management of hemophilia A. Once formed, these inhibitory antibodies abrogate the activity of FVIII, resulting in loss of hemostatic efficacy and patients are subjected to increased risk of bleeding tendencies. Current treatment options after inhibitor development are expensive and ineffective in some cases. Therefore, treatment strategies that can prevent inhibitor formation is an effective approach in the management of hemophilia A. OBJECTIVES: We aimed to evaluate and discuss the use of a tolerogenic form of FVIII as an immunotherapy strategy to prevent inhibitor risk. METHODS: FVIII was associated with nanoparticles containing lysophosphatidylserine (Lyso-PS) and administered to hemophilia A mice via intravenous route. These animals then received weekly rechallenge injections with free FVIII, and plasma was collected at the end of the study to evaluate for inhibitor development. To investigate whether Lyso-PS nanoparticles influence the plasma survival of FVIII, a pharmacokinetic study following a single intravenous administration of FVIII in the presence and absence of Lyso-PS nanoparticles was performed. For dosing convenience, the tolerogenic effect of Lyso-PS nanoparticles following oral administration was also examined. RESULTS AND CONCLUSIONS: The results demonstrated that FVIII associated with Lyso-PS nanoparticles significantly reduced inhibitor development while improving plasma survival of FVIII following intravenous administration, suggesting a multifunctional FVIII form to improve clinical utility. Additionally, reduction in inhibitor formation can also be achieved using Lyso-PS nanoparticles through the user-friendly oral route of administration.
引用
- Nguyen NH, Dingman RK, Balu-Iyer SV, et al. Tolerogenic form of Factor VIII to prevent inhibitor development in the treatment of Hemophilia A. J Thromb Haemost. 2021. PMID: 34390536. doi:10.1111/jth.15497
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。